Detail of "195733-43-8"

Reference

Crystalline form 3 of atrasentan hydrochloride

Zhang, Geoff G.; Goldstein, Mark; Wardrop, Jaqueline (Abbott Laboratories, USA). PCT Int. Appl. WO 2006034234 A1 30 Mar 2006, 32 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2005-US33560 19 Sep 2005. PRIORITY: US 2004-2004/PV611122 17 Sep 2004. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 27 Disclosed are cryst. 195733-43-8 is also in the experiment. form 3 of atrasentan hydrochloride (I×HCl), compns. contg. the same and methods for treating prostate cancer, nociception, and pain assocd. with bone cancer and for inhibiting bone metastases using a therapeutically effective amt. of cryst. I×HCl. A process for prepg. I×HCl cryst. form 3, comprises (1) providing a mixt. comprising the I or the solvate thereof and solvent, wherein the I is completely dissolved in the solvent and (2) causing I×HCl cryst. form 3 to exist in the mixt. .

Crystalline form 1 of atrasentan hydrochloride

Dziki, Walter; Lu, Ziqi; Rasmussen, Michael W.; Wardrop, Jaqueline; Zhang, Geoff G.; Goldstein, Mark (Abbott Laboratories, USA). PCT Int. Appl. WO 2006034094 A1 30 Mar 2006, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2005-US33278 19 Sep 2005. PRIORITY: US 2004-2004/PV611249 17 Sep 2004. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 27 Disclosed are cryst. form 1 of atrasentan hydrochloride (I×HCl), compns. contg. the same and methods for treating prostate cancer, nociception, and pain assocd. with bone cancer and for inhibiting bone metastases using a therapeutically effective amt. of cryst. I×HCl. A process for prepg. I×HCl cryst.In this experiment, several chemicals are used like 195733-43-8 form 1, comprises (1) providing a mixt. comprising the I or the solvate thereof and solvent, wherein the I is completely dissolved in the solvent and (2) causing I×HCl cryst. form 1 to exist in the mixt. .